nach oben

PharmacoEconomics

Erschienen in:

01.11.2007 | Editorial

Warfarin Pharmacogenetics

Economic Considerations

verfasst von: Dr Dyfrig A. Hughes, Munir Pirmohamed

Erschienen in: PharmacoEconomics | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Excerpt

Warfarin is a coumarin anticoagulant proven to be efficacious for the treatment and prevention of thromboembolic events in patients with chronic atrial fibrillation, prosthetic heart valves, venous thrombosis and pulmonary embolism. In patients who have atrial fibrillation, for instance, anticoagulation well controlled with warfarin reduces the occurrence of stroke by approximately 60%, compared with only 20% with antiplatelet agents.[1] …

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867PubMed

Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075–1080PubMedCrossRef

Wittkowsky AK. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care 2004; 10: S297–S306; discussion S312-7PubMed

Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996; 335: 540–546PubMedCrossRef

Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11–17PubMedCrossRef

Kearon C, Ginsberg JS, Kovacs MJ, et al. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631–639PubMedCrossRef

Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167 (13): 1414–1419PubMedCrossRef

Oake N, Fergusson DA, Forster AJ, et al. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007; 176 (11): 1589–1594PubMed

van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155–1166PubMedCrossRef

10.

Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329 (7456): 15–19PubMedCrossRef

11.

Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7 (2): 99–111PubMedCrossRef

12.

US Food and Drug Administration. New labeling information for warfarin (marketed as Coumadin). August 16, 2007 [online]. Available from URL: http://www.fda.gov/cder/drug/info page/warfarin/default.htm [Accessed 2007 24 Sep]

13.

Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004; 22 (8): 481–493PubMedCrossRef

14.

You JHS, Chan FCW, Wong RSM, et al. The potential clinical and economic outcomes of pharmacogenetics oriented management of warfarin therapy: a decision analysis. Thromb Haemost 2004; 92: 590–597PubMed

15.

Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manag Care 2003; (7): 493–500

16.

Schalekamp T, Boink GJ, Visser LE, et al. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 2006; 79: 511–520PubMedCrossRef

17.

McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin. AEI-Brooking Joint Center for Regulatory Studies Working Paper 06-23, November 2006 [online]. Available from URL: http://www.aei-brookings.org/publications/abstr act.php?.pid =1127 [Accessed 2007 Sep 4]

18.

Veenstra DL. The cost-effectiveness of warfarin pharmacogenomics. J Thromb Haemost 2007; 5: 1974–1975PubMedCrossRef

19.

Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367 (9508): 404–411PubMedCrossRef

Titel: Warfarin Pharmacogenetics
Economic Considerations
verfasst von: Dr Dyfrig A. Hughes
Munir Pirmohamed
Publikationsdatum: 01.11.2007
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 11/2007
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200725110-00001

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis

Economic Evaluations of Calcineurin Inhibitors in Renal Transplantation

The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary

It’s Time to Choose the Study Design!

Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia